General Updates

3M India Limited 5th Floor Marksquare 61, St Marks Road Bengaluru 560001, India Tel: +91 80 22231414 www.3M.com/in October 26, 2026 Corporate Relationship Department BSE Limited 1st Floor, New Trading Ring, Rotunda Building P.J. Towers, Dalal Street, Fort Mumbai - 400 001 Scrip Code - 523395 The Secretary National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex Bandra (E), Mumbai – 400 051 Scrip Code – 3MINDIA Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ref: Amendment of the agreements Regd Office: Plot No 48-51 Electronics City, Bangalore 560100 CIN No: L31300KA1987PLC013543 Email: investorhelpdesk.in@mmm.com executed in relation to the health care business. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to the disclosure made on November 10, 2023 and April 1, 2024 in respect of the approval granted by the board of directors of 3M India Limited (“Company”) for (a) entering into the binding term sheet by the Company with 3M Healthcare US Opco, LLC (US), 3M Healthcare LATAM/APAC Export Corporation (US), Solventum Intellectual Properties Company (formerly known as 3M Healthcare Intellectual Properties Company) (US) and 3M Unitek Corporation (US) (collectively ‘Solventum’), which set-out the key terms and conditions for the licensed manufacturing, reselling and distributorship, and sales agent agreements to be entered into between the Company and the aforesaid entities in relation to the health care business of the Company, and (b) authorizing the senior management of the Company to execute the aforesaid agreements, we hereby inform you that the Company has entered into the following agreements (collectively, the “Transaction Agreements”): i. Distribution Agreement with 3M Healthcare US Opco, LLC and 3M Healthcare LATAM/APAC Export Corporation on March 31, 2024 (“Distribution Agreement”); and ii. Licensed Manufacturer and Reseller Agreement with Solventum Intellectual Properties Company, 3M Healthcare US Opco, LLC, and 3M Healthcare LATAM/APAC Export Corporation on March 31, 2024 (“LMRA”); and iii. Sales Agent Agreement with 3M Unitek Corporation on March 31, 2024. The Transaction Agreements came into effect on March 31, 2024. In this relation, we would wish to inform you of the change of name of 3M Healthcare US Opco, LLC to Solventum US LLC and change in name of 3M Healthcare Intellectual Properties Company to Solventum Intellectual Properties Company. Also, we have attached the previous disclosure on this subject matter hereto as Annexure 1. Separately, the Company hereby wishes to inform that the concerned parties to the Transaction Documents have agreed to amend certain terms of the Transaction Documents, including the Distribution Agreement and the LMRA by executing an amendment agreement (“2nd Amendment Agreement”). It is hereby clarified that the concerned parties will execute an amendment to the LMRA within 30 (thirty) calendar days from the date of execution of the 2nd Amendment Agreement. The board of directors of the Company, on October 26, 2026 reviewed and approved the key commercial terms of the proposed amendments to the 2nd Amendment Agreement and has authorized the execution of the relevant 2nd Amendment Agreement and subsequent amendment to LMRA. Pursuant thereto, we would like to disclose the key terms of the 2nd Amendment Agreement, as stipulated in Annexure 2 to this disclosure. The proposed amendments include, among other matters: : (i) removing certain products from the scope of the Distribution Agreement subject to fulfilment of certain conditions agreed to among 3M India, Solventum and Thermo Fisher, following the divestiture by Solventum of the corresponding product portfolio to Thermo Fisher; and (ii) extending the term of the Distribution Agreement in respect of the products other than those forming part of the product portfolio divested by Solventum to Thermo Fisher by an additional 2 (two) years. Accordingly, the Distribution Agreement shall, in respect of the continuing products, continue in force for a period of 7 (seven) years from the date of execution of the Distribution Agreement. The material terms of the proposed 2nd Amendment Agreement are set out in detail in Annexure 2 to this disclosure. Kindly bring this to the notice of the members of the Stock Exchange. Thanking you Yours faithfully For 3M India Limited Pratap Rudra Bhuvanagiri Company Secretary & Compliance Officer Annexure 1 3M India Limited WeWork Prestige Central 3rdFloor, 36 Infantry Road Bengaluru 560001, India Tel: +91 80 22231414 www.3M.com/in To, April 1, 2024 1. BSE Limited 1st Floor, New Trading Ring, Rotunda Building P.J. Towers, Dalal Street, Fort Mumbai 400001 Scrip Code - 523395 2. National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai 400051 Scrip Code 3MINDIA Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ref: Agreementsexecuted in relation to the health care business. Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to the disclosure made to you on November 10, 2023 in respect of the approval granted by the board of directors of Company for entering into the binding term sheet by the Company with 3M Healthcare US Opco, LLC (US), 3M Healthcare LATAM/APAC Export Corporation (US), Solventum Intellectual Properties Company (US) and 3M Unitek Corporation (US), which sets-out the key terms and conditions for the licensed manufacturing, reselling and distributorship, and sales agent agreementsto be entered into between the Company and the aforesaid entities in relation to the health care business of the Company, and authorising the senior management of the Company to execute the aforesaid agreements, we hereby inform you that the Company has entered into the following agreements: (a)Distribution Agreement with 3M Healthcare US Opco, LLC and 3M Healthcare LATAM/APAC Export Corporation on March 31, 2024. (b)Licensed Manufacturer and Reseller Agreement with Solventum Intellectual Properties Company, 3M Healthcare USOpco, LLC, and 3M Healthcare LATAM/APACExport Corporation on March 31, 2024 and (c)Sales Agent Agreement with 3M Unitek Corporation on March 31, 2024. The above agreements came into effect on March 31, 2024. Further, it is hereby informed that 3M Healthcare Intellectual Properties Company, being one of the counterparties under the aforesaid term sheet has, after execution of the aforesaid term sheet, changed its name to Solventum Intellectual Properties Company. Also, we have attached the previous disclosure on this subject matter hereto as Annexure. Kindly bring this to the notice of the members of the Stock Exchange. Thanking you Yours faithfully For 3M India Limited Pratap RudraBhuvanagiri Company Secretary &Compliance Officer Regd Office: Plot No 48-51 Electronics City, Bangalore 560100 CIN No: L31300KA1987PLC013543 Annexure 2 Key terms of the 2nd Amendment Agreement are set out herein below: Subject Key Terms Background and The parties to the Distribution Agreement desire to remove certain products forming part of purpose the product portfolio divested by Solventum to Thermo Fisher from the scope of Solventum’s exclusivity commitment to the Company, and accordingly the definition of TF Divested Products (as detailed below) has been added. The parties to the Distribution Agreement and LMRA desire to extend the term of the aforesaid agreements for the products other than those forming part of the product portfolio divested by Solventum to Thermo Fisher for an additional 2 (two) years. New definition: The definition of the TF Divested Products is added and shall mean the products listed in "TF Divested Exhibit A of the 2nd Amendment Agreement, and which will be removed [Showing first 8,000 characters — download PDF for full document]